<DOC>
	<DOC>NCT00660374</DOC>
	<brief_summary>This trial is conducted in South America. This trial aims for a comparison of the safety and efficacy of insulin NPH and a new insulin formulation on blood glucose control.</brief_summary>
	<brief_title>Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes for at least 12 months Current NPH treatment for at least 3 months alone or as the only insulin in combination with OADs Body Mass Index (BMI) less than or equal to 40 kg/m2 HbA1c less than or equal to 9.5% FPG less than or equal to 12 mmol/L Treatment with Glucagonlike peptide 1 mimetics or dipeptityl peptidase IV inhibitors Treatment with more than 1 IU/kg NPH insulin daily Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the Investigator Known or suspected allergy to trial products or related products Receipt of any investigational drug within one month prior to this trial Any other condition that the Investigator feels would interfere with trial participation or evaluation of results, e.g. shiftworkers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>